Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Inexpensive Test Bests PSA for Prostate Cancer Screening

Qun Huo (University of Central Florida)

3 April 2015. An inexpensive lab test using gold nanoparticles is shown in a new study to be more sensitive and specific in screening for prostate cancer than the standard prostate-specific antigen or PSA screen. A team from University of Central Florida in Orlando, led by materials . . . → Read More: Inexpensive Test Bests PSA for Prostate Cancer Screening

Astellas Getting First Access to Leukemia Antibody

Acute myeloid leukemia cells (Cancer Genome Atlas)

3 April 2015. MD Anderson Cancer Center in Houston is granting Astellas Pharma Inc. in Tokyo an option to license MD Anderson’s discovery of a synthetic antibody showing promise as a treatment for acute myeloid leukemia. For the licensing option, MD Anderson could earn up to . . . → Read More: Astellas Getting First Access to Leukemia Antibody

White House Economist: Lower Health Costs Benefit Economy

Jason Furman (A. Kotok)

2 April 2015. President Obama’s chief economic adviser said lower health care costs since passage of the Affordable Care Act in 2010 are benefiting the overall U.S. economy and lowering Federal deficits. Jason Furman, who chairs the president’s Council of Economic Advisers, made his remarks today in a briefing . . . → Read More: White House Economist: Lower Health Costs Benefit Economy

Kaiser Permanente to Study Autism Genetics

(NIST.gov)

1 April 2015. The managed-care provider Kaiser Permanente in Oakland, California is collecting genetic and environmental data from 5,000 of its members to better pinpoint causes of autism spectrum disorder. The 3 year project, which includes establishing a databank for further research into autism, is funded by a $4.6 million grant from . . . → Read More: Kaiser Permanente to Study Autism Genetics

$150 Million Raised for NYC Life Science Start-Ups

(A. Kotok)

1 April 2015. A consortium of public and private funding sources raised $150 million to invest in new life science companies located in New York City. The Early Stage Life Sciences Funding Initiative exceeded its original $100 million goal by half, and seeks to start 15 to 20 new businesses in . . . → Read More: $150 Million Raised for NYC Life Science Start-Ups